Healthcare
FamiCord AG(VTIAF)
Live Price
Offline$6.38
+0.00% today
1Y Change
+39.55%
Window
Jun 23, 2025 โ Jun 12, 2026
- Market Cap
- $80.00M
- Revenue Growth
- +7.2%
- EPS Growth
- +48.6%
- Dividend Yield
- 0.0%
Coverage: 252 bars ยท Jun 23, 2025 โ Jun 12, 2026
Research Briefing
A compact read on the setup, peer context, quarterly changes, and recent earnings reaction.
Research Snapshot
FamiCord AG (VTIAF) is a Healthcare stock with a market cap of $80.00M and listed on OTC. The stock last traded around $6.38 and up 39.5% across the available one-year price window (Jun 23, 2025 โ Jun 12, 2026). Baseline metrics include revenue growth of +7.2%, EPS growth of +48.6%, a dividend yield of 0.0%. What stands out right now is revenue +7.2%, EPS +48.6%, free cash flow -104.6% with operating margin -2.6% and ROIC -2.0%. Valuation is more restrained than many high-expectation growth names at price/sales 0.9. Stock Foundry combines VTIAF price history, valuation, growth, dividend context, earnings, analyst forecasts, news, related Healthcare peers on this page.
Sector Context
How this name stacks up against nearby peers on first-pass metrics.
Revenue Growth
Near sector median
+7.2% vs +7.6% peer median
Operating Margin
Below sector median
-2.6% vs +19.4% peer median
What Changed This Quarter
Latest report context and the signals most likely to have changed the story.
Latest report is on the board
2026 was reported on Jun 3, 2026, but the surprise data is still limited.
The operating story is still moving forward
Revenue is running at +7.2% and EPS at +48.6%, with operating margin around -2.6%.
Earnings Reaction Memory
How the stock has tended to move after recent reports.
Across the last 3 reported quarters, the stock averaged 0.0% over the next 5 trading days and finished higher after 0 of those reports.
View quarter-by-quarter reaction table
| Quarter | EPS ฮ | 1D | 5D | 20D |
|---|---|---|---|---|
2026 Jun 3, 2026 | โ | +0.0% | +0.0% | โ |
2026 Mar 31, 2026 | โ | +0.0% | +0.0% | +0.0% |
2025 Aug 27, 2025 | โ | +0.0% | +0.0% | +0.0% |
Benchmark Comparison
Normalized Performance vs SPY
Compare this ticker against a broad index, growth benchmark, or sector ETF using a shared 1Y normalization window.
VTIAF
โ
Normalized return
SPY
โ
S&P 500
Excess Return
โ
Relative to SPY
VTIAF Max Drawdown
-8.93%
Trailing 1Y
SPY Max Drawdown
โ
Trailing 1Y
Calendar-Year Returns
Uses the longest available daily history for VTIAF and SPY.
Company Overview
FamiCord AG
Other OTC
VITA 34 AG engages in the collection, processing, and storage of stem cells from umbilical cord blood and tissue in Germany, Spain, and internationally. It also develops cell therapeutic procedures; cell and gene therapies; cryopreservation of endogenous immune cells; and CAR-T. In addition, the company manufactures advanced therapy medicinal products based on mesenchymal stem cells for experimental treatment by specialized medical institutions; preserves stem cells from perinatal tissue and adult body fat; and engages in the contract manufacturing of pharmaceutical intermediates. VITA 34 AG was founded in 1997 and is based in Leipzig, Germany.
- Leadership
- Jakub Julian Baran
- IPO Date
- Feb 18, 2020
- Employees
- 783
- Street Address
- Deutscher Platz 5a
- Mailing
- Leipzig, 04103
- Region
- Leipzig, DE
- Reporting Currency
- USD
- Investor Line
- 49 341 48792 40
- Last Updated
- May 5, 2026
Key Fundamentals
Valuation, growth, profitability, and balance sheet signals.
Valuation
- P/E
- โ
- EV/EBITDA
- 11.2
- Price/Sales
- 0.9
- Price/Book
- 10.7
Growth
- Revenue
- +7.2%
- EPS
- +48.6%
- Free Cash Flow
- -104.6%
Profitability
- Gross Margin
- 53.1%
- Operating Margin
- -2.6%
- Net Margin
- -7.2%
- ROE
- -52.7%
- ROIC
- -2.0%
Balance Sheet
- Debt/Equity
- 3.30
- Current Ratio
- 0.66
Earnings Reports
Latest News
Official Releases
Company announcements and filings-style updates.
Next Step
Keep the research moving
After the overview, the strongest next step is usually chart context or a tighter compare set.